Abstracts

Long-Term Immunodominant Profile of SARS-CoV-2 T-Cell Responses in Hybrid Immunity

Background: Characterization of long-term T-cell immunity against SARS-CoV-2 proteome is critical for understanding the implications of virus-specific hybrid immunity in protecting against re-infection and advancing novel vaccine designs. Here, we conducted a high-resolution mapping of the breadth and magnitude of T-cell responses to the entire SARS-CoV-2 proteome over a 2-year follow-up period in individuals with…

Complement Activation as a Mechanism of Protection by SARS-CoV-2 mRNA Vaccines in Men With HIV-1

Background: People living with HIV (PLWH) are recommended to be fully vaccinated against SARS-CoV-2. However, men with HIV-1 (MWH) respond to the COVID-19 vaccine with lower immunoglobulin binding and neutralization titers against SARS-CoV-2 than men without HIV-1 (MWOH). Although neutralization is an important protective mechanism against SARS-CoV-2, other mechanisms can play a key role in…

Mucosal HIV Vaccine Targeting Host Epithelial Stem Cells for Long-Term Immunity

Background: Background: HIV transmission occurs predominantly across mucosal surfaces; an ideal vaccine should be to target HIV at mucosal entry sites to prevent infection. We developed a SIV single-cycle replication-deficient vaccine under the control of the involucrin promoter, which was tested for its ability to drive SIV expression in terminally differentiated epithelial cells, induce mucosal…

Developing Novel HIV-1 Env Proteins That Efficiently Engage the Unmutated Forms of VRC01-Class Abs

Background: VRC01-class antibodies are potent and broadly neutralizing antibodies (bnAbs) that protect animals from experimental S/HIV infection and have been shown to prevent HIV-1 acquisition in two phase 3 clinical trials. These antibodies target the CD4 binding site (CD4-BS) of the HIV-1 envelope glycoprotein (Env), but their predicted germline (gl) forms bind the Envs inefficiently.…

Enhancing HIV Vaccine Efficacy via Langerhans Cell-Targeted Env Trimers

Background: Developing an effective HIV-1 vaccine is contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Previous studies have shown success in targeting skin Langerhans cells…

Sex-Based Differences in Antibody Responses Induced by a Native-Like HIV-1 Envelope Trimer Vaccine

Background: A protective vaccine would be the most powerful tool towards reducing HIV-1 infections worldwide and sustainably ending the AIDS epidemic as a public health threat. We assessed the safety and immunogenicity of ConM SOSIP.v7, a native-like envelope trimer vaccine based on an HIV-1 group M consensus sequence, in HIV-negative adults. Methods: 24 individuals were…

Adenosine Deaminase-1 Enhances HIV-Specific Responses to a HIV Trimeric Envelope DNA Vaccine

Background: Human immunodeficiency virus (HIV) remains a prominent global health threat for which no prophylactic vaccine is available. Extensive research efforts have resulted in immunogens, including SOSIP trimers, that closely mimic the native envelope (Env) glycoprotein conformation and consistently induce autologous neutralizing responses. Recently, a novel triple tandem trimer (TTT) platform has been used to…

Machine Learning-Guided Generation of a Combination of Broadly Neutralizing Sarbecovirus Antibodies

Background: Sarbecoviruses represent a subgenus of coronaviruses including strains mostly circulating in bats and at risk of zoonotic spillover as well as strains that can infect humans (SARS-CoV-1 and SARS-CoV-2). Over the past 20 years, SARS-CoV-1 was responsible for an outbreak in Asia while SARS-CoV-2 initiated a global pandemic and remains a continuous health threat…

An Efficient Envelope Genotypic Assay to Identify bNAb Susceptibility in Infants with HIV

Background: HIV-1 envelope (Env)-specific broadly neutralizing antibodies (bNAbs) have several potential clinical benefits including in infants: Infants have limited tolerable antiretroviral treatment (ART) options, given daily for prevention and twice daily for treatment. In contrast, bNAbs with modified Leucine-Serine (LS) Fc receptors permit infrequent subcutaneous dosing. Moreover, unlike ART, bNAbs may facilitate viral reservoir reduction…